NEW YORK, May 8, 2024 /PRNewswire/ — The global workforce analytics market size is estimated to grow by USD 1.86 billion from 2023 to 2027, according to Technavio. This growth is expected to occur at a Compound Annual Growth Rate (CAGR) of almost 15.42% during the forecast period. To…
Month: May 2024
NEW YORK, May 8, 2024 /PRNewswire/ — The global instant soup market size is estimated to grow by USD 3.88 bilion from 2023 to 2027, according to Technavio. This growth is expected to occur at a Compound Annual Growth Rate (CAGR) of over 3.74% during the forecast period. To understand…
NEW YORK, May 8, 2024 /PRNewswire/ — The global instant soup market size is estimated to grow by USD 3.88 bilion from 2023 to 2027, according to Technavio. This growth is expected to occur at a Compound Annual Growth Rate (CAGR) of over 3.74% during the forecast period. To understand…
NEW YORK, May 8, 2024 /PRNewswire/ — The global instant soup market size is estimated to grow by USD 3.88 bilion from 2023 to 2027, according to Technavio. This growth is expected to occur at a Compound Annual Growth Rate (CAGR) of over 3.74% during the forecast period. To understand…
LOS ANGELES, May 8, 2024 /PRNewswire/ — Glancy Prongay & Murray LLP (“GPM”) announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Innoviz Technologies Ltd. (“Innoviz” or the “Company”) (NASDAQ: INVZ). Class Period:…
LOS ANGELES, May 8, 2024 /PRNewswire/ — Glancy Prongay & Murray LLP (“GPM”) announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Innoviz Technologies Ltd. (“Innoviz” or the “Company”) (NASDAQ: INVZ). Class Period:…
LOS ANGELES, May 8, 2024 /PRNewswire/ — Glancy Prongay & Murray LLP (“GPM”) announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Innoviz Technologies Ltd. (“Innoviz” or the “Company”) (NASDAQ: INVZ). Class Period:…
PT217 is Phanes’ first-in-class bispecific antibody targeting DLL3 and CD47; atezolizumab (TECENTRIQ®) is Roche’s anti-PD-L1 monoclonal antibody The clinical supply agreement will focus on evaluating PT217 in combination with atezolizumab for the treatment of small cell lung cancer…
PT217 is Phanes’ first-in-class bispecific antibody targeting DLL3 and CD47; atezolizumab (TECENTRIQ®) is Roche’s anti-PD-L1 monoclonal antibody The clinical supply agreement will focus on evaluating PT217 in combination with atezolizumab for the treatment of small cell lung cancer…
PT217 is Phanes’ first-in-class bispecific antibody targeting DLL3 and CD47; atezolizumab (TECENTRIQ®) is Roche’s anti-PD-L1 monoclonal antibody The clinical supply agreement will focus on evaluating PT217 in combination with atezolizumab for the treatment of small cell lung cancer…